- Clearmind Medicine (CSE:CMND) has revealed results from its weight loss pre-clinical trial
- The treatment used in the trial combined the company’s MEAI psychedelic treatment and SciSparc’s Palmitoylethanolamide
- The trial’s goal was to identify optimal doses for the combination and to observe their safety and impact on metallic and behavioural parameters
- Shares of Clearmind Medicine are down 12.86 per cent to C$4.74 as of 12:23 pm ET
Clearmind Medicine (CSE:CMND) revealed results from its weight loss preclinical trial on Tuesday led by professor Joseph Tam from the Hebrew University of Jerusalem.
In a news release, the company stated results from the pre-clinical trial showed the treatments had positive effects on fat oxidation, weight loss and reduced appetite.
The treatments used in the trial combined its MEAI psychedelic treatment and SciSparc’s treatment palmitoylethanolamide (PEA).
MEAI is used to treat various conditions such as obesity and metabolic disorders as well as depression, while PEA is an anti-inflammatory agent and the active ingredient in SciSparc’s proprietary CannAmide.
The trial’s goal was to identify the optimal dosage for treatment combinations, to observe their safety and impact on various metabolic and behavioral parameters including fat oxidation, locomotor activity, and feeding behaviour.
“I believe that our proprietary drug candidate, MEAI, is a potentially better and safer option compared to other weight loss drugs currently on the market due to previous and current positive results and the very good safety profile,” Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, said in a statement. “Clearmind’s treatment targets fat loss while maintaining and elevating energy levels, motivation and other positive influences. These latest results strengthen our confidence in our MEAI-based treatment, including our combination treatment with SciSparc’s PEA.”
Roughly 14 different treatment groups were used with a total of 84 animals that received a wide range of doses of MEAI with or without a dose of PEA dose of 25 mg/kg.
Results indicated a degree of tolerance as well as a reduction of food consumption and elevated energy expenditure and fat oxidation.
Clearmind Medicine is a psychedelic pharmaceutical biotech company focused on discovering and developing novel psychedelic treatments for health problems such as alcohol use disorder. The company’s intellectual portfolio also includes 15 patent families.
Shares of Clearmind Medicine are down 12.86 per cent to C$4.74 as of 12:23 pm ET.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.